• Home
  • Search Results

Search Results

Janell Markey
Young Adult (18-34)
4 studies match your search
Open

Comparison of drug combinations to prevent graft-versus-host disease after stem cell transplant

Have you been diagnosed with a blood cancer that can be treated by transplant? If so, you might be eligible to take part in a study that will compare combinations of drugs to see which combination is better at preventing graft-versus-host disease.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Open

Severe Aplastic Anemia Treatment Study

Have you been diagnosed with Severe Aplastic Anemia (SAA), but don't have a matched sibling donor? If so, you may be able to take part in a study to see if a bone marrow transplant from a donor that is not related can help treat your disease. Compensation provided.

Age & Gender
  • 18 years ~ 75 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions

A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease.

Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal

Age & Gender
  • 12 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Open

Reduced Dose of Cyclophosphamide to Prevent Graft versus Host Disease after Stem Cell Transplant

Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research